NI201600012A - Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonistas de receptores muscarínicos así como actividad agonistas del receptor b2 adrenérgico. - Google Patents

Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonistas de receptores muscarínicos así como actividad agonistas del receptor b2 adrenérgico.

Info

Publication number
NI201600012A
NI201600012A NI201600012A NI201600012A NI201600012A NI 201600012 A NI201600012 A NI 201600012A NI 201600012 A NI201600012 A NI 201600012A NI 201600012 A NI201600012 A NI 201600012A NI 201600012 A NI201600012 A NI 201600012A
Authority
NI
Nicaragua
Prior art keywords
derivatives
activity
salts
hidroxiquinolin
ona
Prior art date
Application number
NI201600012A
Other languages
English (en)
Inventor
Carrera Francesc Carrera
Prat Quiñones María
Puig Duran Carlos
Pajuelo Lorenzo Francesca
Antonio Perez Andres Juan
Julia Jane Montserrat
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201600012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of NI201600012A publication Critical patent/NI201600012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a sales de adición cristalinas de (i) derivados de 8-hidroxiquinolin-2(1H)-ona y (ii) un ácido dicarboxílico, un ácido sulfónico o una sulfimida, o un solvato farmacéuticamente aceptables de las mismas.
NI201600012A 2013-07-25 2016-01-20 Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonistas de receptores muscarínicos así como actividad agonistas del receptor b2 adrenérgico. NI201600012A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25

Publications (1)

Publication Number Publication Date
NI201600012A true NI201600012A (es) 2016-10-10

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201600012A NI201600012A (es) 2013-07-25 2016-01-20 Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonistas de receptores muscarínicos así como actividad agonistas del receptor b2 adrenérgico.

Country Status (36)

Country Link
US (1) US9579316B2 (es)
EP (1) EP3024489B1 (es)
JP (1) JP6374962B2 (es)
KR (1) KR102338155B1 (es)
CN (2) CN105492027A (es)
AR (1) AR097079A1 (es)
AU (1) AU2014295028B2 (es)
BR (1) BR112016001295B1 (es)
CA (1) CA2917596C (es)
CL (1) CL2016000187A1 (es)
CR (1) CR20160043A (es)
CY (1) CY1122920T1 (es)
DK (1) DK3024489T3 (es)
DO (1) DOP2016000011A (es)
EA (1) EA035436B1 (es)
ES (1) ES2788627T3 (es)
HK (1) HK1219043A1 (es)
HR (1) HRP20200670T1 (es)
HU (1) HUE049441T2 (es)
IL (1) IL243173B (es)
LT (1) LT3024489T (es)
MX (1) MX360837B (es)
MY (1) MY184681A (es)
NI (1) NI201600012A (es)
NZ (1) NZ715128A (es)
PE (1) PE20160173A1 (es)
PH (1) PH12016500125B1 (es)
PL (1) PL3024489T3 (es)
PT (1) PT3024489T (es)
RS (1) RS60185B1 (es)
SG (1) SG11201510682YA (es)
SI (1) SI3024489T1 (es)
TW (1) TWI641373B (es)
UY (1) UY35678A (es)
WO (1) WO2015011244A1 (es)
ZA (1) ZA201509203B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) * 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN107074833B (zh) * 2015-07-21 2021-05-25 四川海思科制药有限公司 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
TW201835041A (zh) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2020244452A1 (zh) * 2019-06-06 2020-12-10 中国医药研究开发中心有限公司 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
CN117534663A (zh) * 2020-09-28 2024-02-09 正大天晴药业集团股份有限公司 稠合的三并环衍生物及其在药学上的应用
WO2023179758A1 (zh) * 2022-03-25 2023-09-28 正大天晴药业集团股份有限公司 稠合三并环衍生物或其可药用盐的结晶

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
EP0147475B1 (en) 1983-09-26 1987-03-18 MAGIS FARMACEUTICI S.p.A. Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
JPH03178929A (ja) 1989-09-07 1991-08-02 Glaxo Group Ltd 炎症及びアレルギー治療用化合物
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
AU4248597A (en) 1996-09-06 1998-03-26 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
PL205059B1 (pl) 1999-08-20 2010-03-31 Dow Agrosciences Llc Heterocykliczny amid aromatyczny, jego kompozycja grzybobójcza oraz sposób zwalczania lub zapobiegania zakażeniom grzybami
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
DE602004021921D1 (de) 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
MEP9608A (en) 2006-03-20 2010-06-10 Pfizer Ltd Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
RS20090137A (en) 2006-10-04 2010-06-30 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (es) 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
NZ586872A (en) 2008-02-06 2012-03-30 Astrazeneca Ab Spirocyclic amide compounds
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
KR20110022611A (ko) * 2008-06-20 2011-03-07 아스트라제네카 아베 베타２－아드레날린수용체 활성의 조절을 위한, ４－히드록시－２－옥소－２,３－디히드로－１,３－벤조티아졸－７－일 화합물을 포함하는 제약 조성물
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2599778B1 (en) 2009-04-23 2017-04-12 Theravance Respiratory Company, LLC Diamide Compounds having Muscarinic Receptor Antagonist and Beta 2 Adrenergic Receptor Agonist Activity
NZ595810A (en) 2009-04-30 2013-05-31 Teijin Pharma Ltd Quaternary ammonium salt compound
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
WO2012168349A1 (en) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR101650262B1 (ko) 2011-11-11 2016-08-22 화이자 인코포레이티드 2-티오피리미딘온
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
SI2776038T1 (en) 2011-11-11 2018-06-29 Gilead Apollo, Llc ACC INHIBITORS AND THEIR USE
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
HUE037944T2 (hu) 2012-12-06 2018-09-28 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek
CA2893627C (en) 2012-12-06 2021-09-14 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
CL2016000187A1 (es) 2016-08-05
US9579316B2 (en) 2017-02-28
TW201517907A (zh) 2015-05-16
AU2014295028A1 (en) 2016-01-21
MX360837B (es) 2018-11-20
BR112016001295B1 (pt) 2022-07-19
CN112321579A (zh) 2021-02-05
DOP2016000011A (es) 2016-06-15
HK1219043A1 (zh) 2017-03-24
PE20160173A1 (es) 2016-04-13
HRP20200670T1 (hr) 2020-07-10
TWI641373B (zh) 2018-11-21
KR20160034310A (ko) 2016-03-29
LT3024489T (lt) 2020-03-10
MX2016000397A (es) 2016-04-29
CN105492027A (zh) 2016-04-13
PH12016500125A1 (en) 2016-04-25
SG11201510682YA (en) 2016-02-26
JP6374962B2 (ja) 2018-08-15
AU2014295028B2 (en) 2018-05-31
MY184681A (en) 2021-04-16
US20160166566A1 (en) 2016-06-16
ZA201509203B (en) 2017-04-26
ES2788627T3 (es) 2020-10-22
DK3024489T3 (da) 2020-05-04
PT3024489T (pt) 2020-05-05
KR102338155B1 (ko) 2021-12-10
HUE049441T2 (hu) 2020-09-28
WO2015011244A1 (en) 2015-01-29
EP3024489B1 (en) 2020-02-19
AR097079A1 (es) 2016-02-17
UY35678A (es) 2015-02-27
SI3024489T1 (sl) 2020-04-30
CY1122920T1 (el) 2021-10-29
IL243173A0 (en) 2016-02-29
EA201600128A1 (ru) 2016-07-29
PH12016500125B1 (en) 2016-04-25
CR20160043A (es) 2016-04-08
PL3024489T3 (pl) 2020-08-10
EA035436B1 (ru) 2020-06-15
CA2917596C (en) 2021-06-22
JP2016525533A (ja) 2016-08-25
NZ715128A (en) 2019-03-29
BR112016001295A2 (es) 2017-07-25
EP3024489A1 (en) 2016-06-01
RS60185B1 (sr) 2020-06-30
IL243173B (en) 2019-10-31
CA2917596A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
NI201600012A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonistas de receptores muscarínicos así como actividad agonistas del receptor b2 adrenérgico.
CR20150427A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2 (1h)-ona que tienen actividad agonista del receptor b2 adrenérgico así como actividad antagonista del receptor
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
CR20140464A (es) Compuestos de heterociclilo
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
ECSP18010481A (es) Composiciones de plinabulina
PE20151216A1 (es) Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico
CR20150250A (es) Nuevos derivados de piridina
CR20150447A (es) Nuevos derivados de pirazol
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
BR112015023161A8 (pt) derivados de piridin-4-ila
CR20150440A (es) Nuevos derivados de piridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CR20150267A (es) 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il] 1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
CR20140343A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
CR20140564A (es) Derivados de pirimidinona como agentes antimaláricos
NI201500107A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenérgico así como actividad antagonista del receptor muscarínico m3.